AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34136987 — intervention group
Group type: EXPERIMENTAL
Intervention: MT-12 h once-daily for 3 days at three dose levels
Number of subjects: 0
Study 34136987 — intervention group
Group type: EXPERIMENTAL
Intervention: MM-12 h formulation at two dose levels
Number of subjects: 0
Study 34136987 — intervention group
Group type: COMPARATOR
Intervention: Immediate release (IR) formulation (120 mg)
Number of subjects: 0
Study 34137430 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab 300 mg every 8 weeks
Number of subjects: 110
Study 34137430 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab every 4 weeks (model-based simulation)
Number of subjects: 110
Study 34138447 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with a current psychiatric disorder
Number of subjects: 245
Study 34138447 — intervention group
Group type: COMPARATOR
Intervention: Patients without a current psychiatric disorder
Number of subjects: 245
Study 34138447 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients reporting clinically relevant FCR
Number of subjects: 245
Study 34138449 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Electrical Neuromodulation (REN)
Number of subjects: 91
Study 34138594 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded response item response theory
Number of subjects: 0
Study 34138613 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34138816 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA) ≥75th percentile (760.5 MET·min·wk-1) in early-to-mid second trimester
Number of subjects: 2388
Study 34138816 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintaining recommended levels of MVPA from preconception and first trimester through second trimester
Number of subjects: 2388
Study 34138816 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintaining sufficient activity throughout second trimester
Number of subjects: 2388
Study 34138816 — intervention group
Group type: EXPERIMENTAL
Intervention: MVPA of at least 760.0 MET·min·wk-1 in early-to-mid second trimester
Number of subjects: 2388
Study 34138816 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintaining at least 500 MET·min·wk-1 from preconception through second trimester
Number of subjects: 2388
Study 34138888 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 hospitalized patients
Number of subjects: 4704
Study 34138888 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 4704
Study 34138888 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory rate
Number of subjects: 4704
Study 34138888 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate dehydrogenase (LDH)
Number of subjects: 4704
Study 34138888 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 4704
Study 34138888 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatinine values
Number of subjects: 4704
Study 34139688 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracardiac thrombus (ICT)
Number of subjects: 122
Study 34139688 — intervention group
Group type: COMPARATOR
Intervention: Atrial fibrillation (AF)
Number of subjects: 122
Study 34139689 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous bilirubin (TcB) measurement
Number of subjects: 296
Study 34139689 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous bilirubin (TcB) measurement before phototherapy
Number of subjects: 296
Study 34139689 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous bilirubin (TcB) measurement after initiation of phototherapy
Number of subjects: 296
Study 34139689 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous bilirubin (TcB) measurement at the forehead
Number of subjects: 296
Study 34139689 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous bilirubin (TcB) measurement at the sternum
Number of subjects: 296
Study 34139689 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous bilirubin (TcB) measurement among infants born 24-28 weeks
Number of subjects: 296
Study 34139689 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous bilirubin (TcB) measurement among infants born 29-32 weeks
Number of subjects: 296
Study 34139689 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous bilirubin (TcB) measurement among infants born 33-35 weeks
Number of subjects: 296
Study 34139747 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiBP mobile application
Number of subjects: 91
Study 34139864 — intervention group
Group type: EXPERIMENTAL
Intervention: Predilation during TAVR
Number of subjects: 0
Study 34139864 — intervention group
Group type: COMPARATOR
Intervention: No predilation during TAVR (Control)
Number of subjects: 0
Study 34140107 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglyceride levels ≥150 mg/dl
Number of subjects: 3754
Study 34140107 — intervention group
Group type: COMPARATOR
Intervention: Triglyceride levels
Number of subjects: 3754
Study 34140212 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol and ACTH concentrations measured in PMM2-CDG patients
Number of subjects: 43
Study 34140212 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone replacement and/or stress dosing during illness
Number of subjects: 43
Study 34140212 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH low-dose stimulation test
Number of subjects: 43
Study 34140212 — intervention group
Group type: EXPERIMENTAL
Intervention: Upcoming stimulation testing planned
Number of subjects: 43
Study 34140248 — intervention group
Group type: EXPERIMENTAL
Intervention: Onalespib plus erlotinib (erlotinib 150 mg orally every morning and onalespib 120 mg/m)
Number of subjects: 11
Study 34140248 — intervention group
Group type: EXPERIMENTAL
Intervention: Onalespib plus erlotinib
Number of subjects: 11
Study 34140311 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic AF group
Number of subjects: 30
Study 34140311 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic AF group
Number of subjects: 30
Study 34140403 — intervention group
Group type: EXPERIMENTAL
Intervention: APX005M (0.03, 0.1, or 0.3 mg/kg i.v.) with cabiralizumab and nivolumab
Number of subjects: 26
Study 34140403 — intervention group
Group type: EXPERIMENTAL
Intervention: APX005M (0.03, 0.1, or 0.3 mg/kg i.v.) with cabiralizumab without nivolumab
Number of subjects: 26
Study 34140403 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab-containing regimens
Number of subjects: 26
Study 34140403 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 26
Study 34140482 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of osimertinib and dacomitinib
Number of subjects: 0
Study 34140482 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal dosing schedule for osimertinib and dacomitinib
Number of subjects: 0
Study 34140586 — intervention group
Group type: EXPERIMENTAL
Intervention: Single moderate intensity bout of exercise intervention
Number of subjects: 60
Study 34140638 — intervention group
Group type: EXPERIMENTAL
Intervention: CGM097 10-400 mg 3qw
Number of subjects: 51
Study 34140638 — intervention group
Group type: EXPERIMENTAL
Intervention: CGM097 300-700 mg 3qw 2 weeks on/1 week off
Number of subjects: 51
Study 34140638 — intervention group
Group type: EXPERIMENTAL
Intervention: CGM097
Number of subjects: 51
Study 34141612 — intervention group
Group type: EXPERIMENTAL
Intervention: TP53 + RB1 co-mutation in pulmonary LCNEC patients
Number of subjects: 322
Study 34141612 — intervention group
Group type: EXPERIMENTAL
Intervention: TP53 + RB1 co-mutation in extra-pulmonary LCNEC patients
Number of subjects: 322
Study 34141612 — intervention group
Group type: COMPARATOR
Intervention: Comparison with small cell lung cancer (SCLC)
Number of subjects: 322
Study 34141624 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathogenic or clonal pathogenic HRR-only variants
Number of subjects: 501
Study 34141624 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonal pathogenic variants in TP53 genes
Number of subjects: 501
Study 34141624 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathogenic variants in HRR genes
Number of subjects: 501
Study 34141717 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Protein, Low Glycemic Index Diet
Number of subjects: 0
Study 34141717 — intervention group
Group type: COMPARATOR
Intervention: Control Diet (not specified)
Number of subjects: 0
Study 34142073 — intervention group
Group type: EXPERIMENTAL
Intervention: LCR1-LCR2 test
Number of subjects: 4903
Study 34142085 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide
Number of subjects: 20
Study 34142126 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger systolic blood pressure (FSBP) measurement
Number of subjects: 16
Study 34142126 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital-brachial pressure index (DBI) measurement
Number of subjects: 16
Study 34142126 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra/interday reproducibility of FSBP and DBI measurements
Number of subjects: 16
Study 34142256 — intervention group
Group type: EXPERIMENTAL
Intervention: InSep (29-mRNA blood-based host response test)
Number of subjects: 397
Study 34142315 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance with evidence-based clinical guidelines for the management of biliary acute pancreatitis
Number of subjects: 0
Study 34142315 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of new strategies based on identified gaps in compliance
Number of subjects: 0
Study 34142350 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab (300 mg q2w)
Number of subjects: 1553
Study 34142350 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab + TCS
Number of subjects: 1553
Study 34142350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1553
Study 34142350 — intervention group
Group type: COMPARATOR
Intervention: Placebo + TCS
Number of subjects: 1553
Study 34142595 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced daycare of Traditional Chinese Medicine (TCM)
Number of subjects: 401
Study 34143384 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (n=43)
Number of subjects: 280
Study 34143384 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (n=143)
Number of subjects: 280
Study 34143384 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (n=94)
Number of subjects: 280
Study 34143416 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg eplerenone once daily
Number of subjects: 84
Study 34143416 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 84
Study 34143547 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable scaffold (BRS) implantation
Number of subjects: 3326
Study 34143677 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34143682 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle education
Number of subjects: 0
Study 34143867 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist-monitor (cuffless, wireless device)
Number of subjects: 28
Study 34143867 — intervention group
Group type: COMPARATOR
Intervention: Cuff-based ABPM device
Number of subjects: 28
Study 34143969 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib plus pembrolizumab
Number of subjects: 143
Study 34143998 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexinidazole 1800 mg once per day on days 1-4, then 1200 mg on days 5-10
Number of subjects: 238
Study 34143998 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexinidazole
Number of subjects: 238
Study 34144701 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound (POCUS)
Number of subjects: 691
Study 34144918 — intervention group
Group type: EXPERIMENTAL
Intervention: Farm-to-WIC intervention combining behaviorally focused instruction, handouts, farmers' market introduction, field trips, telephone coaching, and recipe demonstrations.
Number of subjects: 297
Study 34144918 — intervention group
Group type: EXPERIMENTAL
Intervention: Farm-to-WIC intervention
Number of subjects: 297
Study 34144918 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 297
Study 34145168 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34145225 — intervention group
Group type: EXPERIMENTAL
Intervention: Idecabtagene vicleucel (ide-cel, bb2121)
Number of subjects: 190
Study 34145225 — intervention group
Group type: COMPARATOR
Intervention: Eligible RRMM (real-world outcomes)
Number of subjects: 190
Study 34145677 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-g FMT
Number of subjects: 77
Study 34145677 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-g FMT
Number of subjects: 77
Study 34145677 — intervention group
Group type: EXPERIMENTAL
Intervention: FMT
Number of subjects: 77
Study 34145979 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobocertinib (20 mg) with itraconazole (200 mg once daily)
Number of subjects: 24
Study 34145979 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobocertinib (160 mg) with rifampin (600 mg once daily)
Number of subjects: 24
Study 34145983 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemic cardiomyopathy (ICM) group
Number of subjects: 496
Study 34145983 — intervention group
Group type: COMPARATOR
Intervention: Non-ischaemic cardiomyopathy (NICM) group
Number of subjects: 496
Study 34145983 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 496
Study 34145983 — intervention group
Group type: EXPERIMENTAL
Intervention: Propensity-score matched analysis
Number of subjects: 496
Study 34146130 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic evaluation for EAS tumors
Number of subjects: 36
Study 34146146 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-layer barbed suture (fishbone suture)
Number of subjects: 0
Study 34146146 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34146238 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-only configuration of the iLet
Number of subjects: 24
Study 34146238 — intervention group
Group type: COMPARATOR
Intervention: Default t
Number of subjects: 24
Study 34146644 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metronidazole treatment for bacterial vaginosis
Number of subjects: 94
Study 34146644 — intervention group
Group type: COMPARATOR
Intervention: Healthy women (no treatment mentioned)
Number of subjects: 94
Study 34146644 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (healthy women and women with BV)
Number of subjects: 94
Study 34146655 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 weeks of exercise training (45 min of intermittent cycling at 60% peak power output wattage)
Number of subjects: 2
Study 34146655 — intervention group
Group type: COMPARATOR
Intervention: Acute exercise (45 min of intermittent cycling at 60% peak power output wattage)
Number of subjects: 2
Study 34146966 — intervention group
Group type: EXPERIMENTAL
Intervention: 4+ ACEs
Number of subjects: 131
Study 34146966 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-3 ACEs
Number of subjects: 131
Study 34147313 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg, intravenously, every 3 weeks for 3 courses)
Number of subjects: 10
Study 34148211 — intervention group
Group type: EXPERIMENTAL
Intervention: ATTRv Glu89Gln amyloidosis patients from Bulgaria
Number of subjects: 91
Study 34148211 — intervention group
Group type: EXPERIMENTAL
Intervention: ATTRv Glu89Gln amyloidosis patients from Italy
Number of subjects: 91
Study 34148505 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranial stenting
Number of subjects: 0
Study 34148505 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34149034 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS)
Number of subjects: 0
Study 34149383 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation intervention, details not specified.
Number of subjects: 0
Study 34149383 — intervention group
Group type: COMPARATOR
Intervention: Control group, details not specified.
Number of subjects: 0
Study 34149468 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief, group- and mosque-based intervention implemented by mosque leaders
Number of subjects: 0
Study 34149587 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic Therapy (RT)
Number of subjects: 44
Study 34149587 — intervention group
Group type: COMPARATOR
Intervention: Conventional Therapy (CT)
Number of subjects: 44
Study 34149627 — intervention group
Group type: EXPERIMENTAL
Intervention: Iscalimab
Number of subjects: 13
Study 34150661 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary ovarian suppression with gonadotropin-releasing hormone agonists (GnRHa)
Number of subjects: 223
Study 34150661 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to the fertility unit for complete oncofertility counseling
Number of subjects: 223
Study 34150661 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreservation technique
Number of subjects: 223
Study 34150661 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone-receptor positive breast cancer
Number of subjects: 223
Study 34150661 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerns about chemotherapy-induced premature ovarian insufficiency and/or infertility
Number of subjects: 223
Study 34150661 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreservation strategies
Number of subjects: 223
Study 34150785 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-intensity conditioning regimen with different haploidentical donors (HIDs) including fludarabine (30 mg/m2)
Number of subjects: 0
Study 34150872 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight change intervention, details not available
Number of subjects: 0
Study 34150923 — intervention group
Group type: EXPERIMENTAL
Intervention: Qvella's FAST HR process for quantifying host gene expression signatures in whole blood
Number of subjects: 128
Study 34151781 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute triiodothyronine administration
Number of subjects: 0
Study 34151947 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Field Ablation (PFA) using a multi-electrode pentaspline catheter with a biphasic waveform
Number of subjects: 59
Study 34151947 — intervention group
Group type: COMPARATOR
Intervention: Thermal Ablation (including 29 radiofrequency ablation, 6 cryoballoon, and 4 visually guided laser balloon)
Number of subjects: 59
Study 34151947 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Field Ablation (PFA)
Number of subjects: 59
Study 34151947 — intervention group
Group type: COMPARATOR
Intervention: Thermal Ablation (RFA)
Number of subjects: 59
Study 34152067 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centred PEP programme with 28-day regimen; PEP availability seven days/week, PEP hotline, out-of-facility medication delivery.
Number of subjects: 124
Study 34152281 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus TB treatment support tools (TB-TSTs)
Number of subjects: 400
Study 34152281 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 400
Study 34152395 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanubrutinib 320 mg once daily
Number of subjects: 32
Study 34152570 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led groups
Number of subjects: 0
Study 34152570 — intervention group
Group type: COMPARATOR
Intervention: Clinician-led groups
Number of subjects: 0
Study 34152570 — intervention group
Group type: COMPARATOR
Intervention: Internet-based eBody Project
Number of subjects: 0
Study 34152570 — intervention group
Group type: COMPARATOR
Intervention: Educational video control
Number of subjects: 0
Study 34152585 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefapixant 50 mg BID for 14 days
Number of subjects: 51
Study 34152585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 34152703 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (low-to-moderate intensity)
Number of subjects: 615
Study 34152898 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous leukemic apoptotic corpse-pulsed dendritic cells (DC) administered at doses of 9 × 10
Number of subjects: 0
Study 34153013 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative point-of-care drug level tests for efavirenz (EFV)
Number of subjects: 83
Study 34153013 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative point-of-care drug level tests for lopinavir (LPV)
Number of subjects: 83
Study 34153013 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative point-of-care drug level tests for dolutegravir (DTG)
Number of subjects: 83
Study 34153013 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated treatment cessation for efavirenz (EFV)
Number of subjects: 83
Study 34153013 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated treatment cessation for lopinavir (LPV)
Number of subjects: 83
Study 34153013 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated treatment cessation for dolutegravir (DTG)
Number of subjects: 83
Study 34153017 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative biomarker panel (including NT-proBNP, hs-CRP, hemoglobin, magnesium)
Number of subjects: 539
Study 34153017 — intervention group
Group type: COMPARATOR
Intervention: Clinical risk factors (EuroSCORE II)
Number of subjects: 539
Study 34153099 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Number of subjects: 4755
Study 34153099 — intervention group
Group type: COMPARATOR
Intervention: Nonplasma (control)
Number of subjects: 4755
Study 34153099 — intervention group
Group type: COMPARATOR
Intervention: Convalescent plasma vs Nonplasma
Number of subjects: 4755
Study 34153116 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptation of management protocols during COVID-19 pandemic, specific details not available.
Number of subjects: 0
Study 34153264 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19 vaccine (two doses given 4-6 weeks apart)
Number of subjects: 54
Study 34153264 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19 vaccine
Number of subjects: 54
Study 34154392 — intervention group
Group type: EXPERIMENTAL
Intervention: NKTR-255
Number of subjects: 0
Study 34154444 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-reported impact of patients' abnormal involuntary movements
Number of subjects: 41
Study 34154444 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of caregiver ratings with patient ratings
Number of subjects: 41